The Transdermal Delivery of Therapeutic Cannabinoids
Recently, several studies have indicated an increased interest in the scientific community regarding the application of <i>Cannabis sativa</i> plants, and their extracts, for medicinal purposes. This plant of enormous medicinal potential has been legalised in an increasing number of coun...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/14/2/438 |
| _version_ | 1797477184582975488 |
|---|---|
| author | Haleh Mahmoudinoodezh Srinivasa Reddy Telukutla Sukhvir Kaur Bhangu Ava Bachari Francesca Cavalieri Nitin Mantri |
| author_facet | Haleh Mahmoudinoodezh Srinivasa Reddy Telukutla Sukhvir Kaur Bhangu Ava Bachari Francesca Cavalieri Nitin Mantri |
| author_sort | Haleh Mahmoudinoodezh |
| collection | DOAJ |
| description | Recently, several studies have indicated an increased interest in the scientific community regarding the application of <i>Cannabis sativa</i> plants, and their extracts, for medicinal purposes. This plant of enormous medicinal potential has been legalised in an increasing number of countries globally. Due to the recent changes in therapeutic and recreational legislation, cannabis and cannabinoids are now frequently permitted for use in clinical settings. However, with their highly lipophilic features and very low aqueous solubility, cannabinoids are prone to degradation, specifically in solution, as they are light-, temperature-, and auto-oxidation-sensitive. Thus, plant-derived cannabinoids have been developed for oral, nasal-inhalation, intranasal, mucosal (sublingual and buccal), transcutaneous (transdermal), local (topical), and parenteral deliveries. Among these administrations routes, topical and transdermal products usually have a higher bioavailability rate with a prolonged steady-state plasma concentration. Additionally, these administrations have the potential to eliminate the psychotropic impacts of the drug by its diffusion into a nonreactive, dead stratum corneum. This modality avoids oral administration and, thus, the first-pass metabolism, leading to constant cannabinoid plasma levels. This review article investigates the practicality of delivering therapeutic cannabinoids via skin in accordance with existing literature. |
| first_indexed | 2024-03-09T21:14:02Z |
| format | Article |
| id | doaj.art-76b52fa06981477ab9368b16adb5044f |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-09T21:14:02Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-76b52fa06981477ab9368b16adb5044f2023-11-23T21:39:21ZengMDPI AGPharmaceutics1999-49232022-02-0114243810.3390/pharmaceutics14020438The Transdermal Delivery of Therapeutic CannabinoidsHaleh Mahmoudinoodezh0Srinivasa Reddy Telukutla1Sukhvir Kaur Bhangu2Ava Bachari3Francesca Cavalieri4Nitin Mantri5The Pangenomics Lab, School of Science, RMIT University, Bundoora, VIC 3083, AustraliaThe Pangenomics Lab, School of Science, RMIT University, Bundoora, VIC 3083, AustraliaSchool of Science, RMIT University, Melbourne, VIC 3000, AustraliaThe Pangenomics Lab, School of Science, RMIT University, Bundoora, VIC 3083, AustraliaApplied Chemistry and Environmental Science, RMIT University, Melbourne, VIC 3000, AustraliaThe Pangenomics Lab, School of Science, RMIT University, Bundoora, VIC 3083, AustraliaRecently, several studies have indicated an increased interest in the scientific community regarding the application of <i>Cannabis sativa</i> plants, and their extracts, for medicinal purposes. This plant of enormous medicinal potential has been legalised in an increasing number of countries globally. Due to the recent changes in therapeutic and recreational legislation, cannabis and cannabinoids are now frequently permitted for use in clinical settings. However, with their highly lipophilic features and very low aqueous solubility, cannabinoids are prone to degradation, specifically in solution, as they are light-, temperature-, and auto-oxidation-sensitive. Thus, plant-derived cannabinoids have been developed for oral, nasal-inhalation, intranasal, mucosal (sublingual and buccal), transcutaneous (transdermal), local (topical), and parenteral deliveries. Among these administrations routes, topical and transdermal products usually have a higher bioavailability rate with a prolonged steady-state plasma concentration. Additionally, these administrations have the potential to eliminate the psychotropic impacts of the drug by its diffusion into a nonreactive, dead stratum corneum. This modality avoids oral administration and, thus, the first-pass metabolism, leading to constant cannabinoid plasma levels. This review article investigates the practicality of delivering therapeutic cannabinoids via skin in accordance with existing literature.https://www.mdpi.com/1999-4923/14/2/438transdermaltopicaltherapeutic cannabinoidsTHCCBDbioavailability |
| spellingShingle | Haleh Mahmoudinoodezh Srinivasa Reddy Telukutla Sukhvir Kaur Bhangu Ava Bachari Francesca Cavalieri Nitin Mantri The Transdermal Delivery of Therapeutic Cannabinoids Pharmaceutics transdermal topical therapeutic cannabinoids THC CBD bioavailability |
| title | The Transdermal Delivery of Therapeutic Cannabinoids |
| title_full | The Transdermal Delivery of Therapeutic Cannabinoids |
| title_fullStr | The Transdermal Delivery of Therapeutic Cannabinoids |
| title_full_unstemmed | The Transdermal Delivery of Therapeutic Cannabinoids |
| title_short | The Transdermal Delivery of Therapeutic Cannabinoids |
| title_sort | transdermal delivery of therapeutic cannabinoids |
| topic | transdermal topical therapeutic cannabinoids THC CBD bioavailability |
| url | https://www.mdpi.com/1999-4923/14/2/438 |
| work_keys_str_mv | AT halehmahmoudinoodezh thetransdermaldeliveryoftherapeuticcannabinoids AT srinivasareddytelukutla thetransdermaldeliveryoftherapeuticcannabinoids AT sukhvirkaurbhangu thetransdermaldeliveryoftherapeuticcannabinoids AT avabachari thetransdermaldeliveryoftherapeuticcannabinoids AT francescacavalieri thetransdermaldeliveryoftherapeuticcannabinoids AT nitinmantri thetransdermaldeliveryoftherapeuticcannabinoids AT halehmahmoudinoodezh transdermaldeliveryoftherapeuticcannabinoids AT srinivasareddytelukutla transdermaldeliveryoftherapeuticcannabinoids AT sukhvirkaurbhangu transdermaldeliveryoftherapeuticcannabinoids AT avabachari transdermaldeliveryoftherapeuticcannabinoids AT francescacavalieri transdermaldeliveryoftherapeuticcannabinoids AT nitinmantri transdermaldeliveryoftherapeuticcannabinoids |